News
Stay tuned and learn Genekor’s latest news and updates on Molecular Oncology.
Molecular Prognosis of Recurrence & Prediction of Chemotherapy Benefit in Colon & Rectal Cancer.
read more
The study by the Genekor Scientific Team on "Polygenic Risk Score in a cohort of 105 Breast Cancer patients previously tested with a multi gene panel for hereditary cancer" was presented at the San Antonio Breast Cancer Symposium 2022 in the form of a Poster.
read moreThrough a two-year program, patients with suspected symptoms from Greece, Romania, Poland, the Czech Republic, Hungary, Ukraine and Israel gain free access to genetic testing with the advanced NGS (New Generation Sequencing) method, which ensures fast and reliable diagnosis of rare diseases.
read more
Another important study by the Genekor Scientific Team on “Next Generation Sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers” was presented by Dr. Floros Ir. Theofanis (Oncologist Pathologist, Military Doctor P.N. - Director, 5th Oncology Clinic of Metropolitan General Hospital) at ESMO CONGRESS 2022 in the form of a Poster.
read moreThe study by the Genekor Scientific Team on "Cascade genetic testing utilized only in 31% of initial families with pathogenic variants in breast cancer genes" was presented at ESMO CONGRESS 2022 in the form of a Poster by Doctors Ziogas Dimitrios (Pathologist-Oncologist A Oncology Clinic Laiko Athens General Hospital) and Giassas Stylianos (Pathologist-Oncologist, Director B, Oncology Clinic, Iasso Hospital).
read moreScientists are to develop the world’s first cure for genetic heart conditions by rewriting DNA in a move hailed as a “defining moment” for cardiovascular medicine.
read moreGenekor Medical S.A. in the context of social responsibility and with the aim of offering quality medical diagnostic services to all children in need, provides the Children's Hospital "Agia Sophia", for the year 2022, free genetic tests specialized in hereditary cardiovascular diseases for 15 underprivileged children with health problems.
read moreRediScore® is a test developed to predict the presence of HRD through the analysis of the tumor’s genomic instability.
read more